068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond

episode

Tomorrow – A podcast by Allianz Research not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

5 year plans don't work. Here's how to build a routine that actually helps you achieve your goals with Dr Rangan Chatterjee 23 min · 21 Sep 2026 · Working Hard with Grace Beverley

Being trans in Britain in 2026 29 min · 21 Sep 2026 · Today in Focus

The Mormon Founding of Salt Lake City 51 min · 21 Sep 2026 · American History Hit

Colin Cowherd Podcast - Caleb Williams Injured, Chargers Have BIG Problems, Broncos Comeback Win, Purdy Was Perfect 1h 13m · 21 Sep 2026 · The Herd with Colin Cowherd

I Sent Robbie Williams A Drunk 5AM Message The Night I Lost My Uncle | Window Kid 1h 2m · 21 Sep 2026 · On The Mend

Chris Fagan's 4th consecutive AFL Grand Final | The Wisdom & Experience of Robert Craddock (21.09.26) 7 min · 21 Sep 2026 · Whateley

Report any issue

Source

Recorded16 Dec 2024

Publishertomorrowbyallianzresearch.podigee.io ↗

Handlerec:19843021

Show notes

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • Read the full report "The weight is over: How GLP-1 treatments are reshaping pharma and beyond": https://t1p.de/cmjmm. • You can also subscribe to our newsletter to stay up to date with all our latest publications: https://ludovicsubran.substack.com/.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in